Omega Therapeutics , Inc. (NASDAQ:OMGA), a biotechnology firm with a market capitalization of $13.45 million, has secured debtor-in-possession (DIP) financing following its voluntary Chapter 11 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New option listings for February 25th include Omega Therapeutics, Inc. (OMGAQ) and Western Digital (WDC). Option delistings effective February 25th include Omega Therapeutics (OMGA), Marinus ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...

Omega Therapeutics, Inc., a biotech firm with a market capitalization of $26.74 million, has entered into a Restructuring Support Agreement (RSA) with Pioneering Medicines 08-B, Inc., an affiliate ...

Omega Therapeutics, Inc., a biotech firm specializing in biological products, has entered into an asset purchase agreement with Pioneering Medicines 08-B, Inc., an affiliate of Flagship Pioneering.

Today, Intrommune Therapeutics, Inc. is excited to announce the publication of a its Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) study evaluating the safety, tolerability, and ...